JP2022535523A5 - - Google Patents
Info
- Publication number
- JP2022535523A5 JP2022535523A5 JP2021571517A JP2021571517A JP2022535523A5 JP 2022535523 A5 JP2022535523 A5 JP 2022535523A5 JP 2021571517 A JP2021571517 A JP 2021571517A JP 2021571517 A JP2021571517 A JP 2021571517A JP 2022535523 A5 JP2022535523 A5 JP 2022535523A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- antigen
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025014697A JP2025090568A (ja) | 2019-05-31 | 2025-01-31 | Ｐａｎ－ノイラミニダーゼ阻害抗体 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962855358P | 2019-05-31 | 2019-05-31 | |
| US62/855,358 | 2019-05-31 | ||
| PCT/US2020/035323 WO2020243572A2 (en) | 2019-05-31 | 2020-05-29 | Pan-neuraminidase inhibiting antibodies |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025014697A Division JP2025090568A (ja) | 2019-05-31 | 2025-01-31 | Ｐａｎ－ノイラミニダーゼ阻害抗体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022535523A JP2022535523A (ja) | 2022-08-09 |
| JP2022535523A5 true JP2022535523A5 (enExample) | 2023-06-05 |
| JP7634231B2 JP7634231B2 (ja) | 2025-02-21 |
Family
ID=73552980
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021571517A Active JP7634231B2 (ja) | 2019-05-31 | 2020-05-29 | Ｐａｎ－ノイラミニダーゼ阻害抗体 |
| JP2025014697A Pending JP2025090568A (ja) | 2019-05-31 | 2025-01-31 | Ｐａｎ－ノイラミニダーゼ阻害抗体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025014697A Pending JP2025090568A (ja) | 2019-05-31 | 2025-01-31 | Ｐａｎ－ノイラミニダーゼ阻害抗体 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US12509503B2 (enExample) |
| EP (1) | EP3980441A4 (enExample) |
| JP (2) | JP7634231B2 (enExample) |
| WO (1) | WO2020243572A2 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7634231B2 (ja) * | 2019-05-31 | 2025-02-21 | ワシントン ユニバーシティ | Ｐａｎ－ノイラミニダーゼ阻害抗体 |
| WO2023201306A1 (en) | 2022-04-14 | 2023-10-19 | Invisishield Technologies Ltd. | Compositions for preventing or treating influenza infections |
| CN119119281B (zh) * | 2024-09-02 | 2025-12-05 | 中山大学·深圳 | 抗神经氨酸酶的单克隆抗体及其应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2007295073A1 (en) | 2006-09-15 | 2008-03-20 | Fraunhofer Usa, Inc. | Influenza antibodies, compositions, and related methods |
| US8734803B2 (en) * | 2008-09-28 | 2014-05-27 | Ibio Inc. | Humanized neuraminidase antibody and methods of use thereof |
| EP2788026A4 (en) * | 2011-12-05 | 2015-08-05 | Univ Duke | V1V2 IMMUNOGENIC |
| TWI702229B (zh) | 2014-12-19 | 2020-08-21 | 美商再生元醫藥公司 | 流行性感冒病毒血球凝集素之人類抗體 |
| WO2016124682A1 (en) * | 2015-02-05 | 2016-08-11 | Janssen Vaccines & Prevention B.V. | Human neutralizing antibodies binding to influenza neuraminidase |
| JP7634231B2 (ja) * | 2019-05-31 | 2025-02-21 | ワシントン ユニバーシティ | Ｐａｎ－ノイラミニダーゼ阻害抗体 |
-
2020
- 2020-05-29 JP JP2021571517A patent/JP7634231B2/ja active Active
- 2020-05-29 EP EP20812656.5A patent/EP3980441A4/en active Pending
- 2020-05-29 WO PCT/US2020/035323 patent/WO2020243572A2/en not_active Ceased
- 2020-05-29 US US17/615,309 patent/US12509503B2/en active Active
-
2025
- 2025-01-31 JP JP2025014697A patent/JP2025090568A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018535650A5 (enExample) | ||
| FI4045533T3 (fi) | Ihmisen monoklonaalisia vasta-aineita vakavalle akuutille koronavirus 2 -hengityselinoireyhtymälle (sars-cov-2) | |
| JP2011528902A5 (enExample) | ||
| FI3484915T3 (fi) | Uusia zikavirusepitooppeihin spesifisesti sitoutuvia vasta-aineita ja niiden käyttöjä | |
| JP2023515271A5 (enExample) | ||
| RU2011105062A (ru) | Нейтрализующие антитела против вируса гриппа а и их использование | |
| JP2023071956A5 (enExample) | ||
| JP2012504955A5 (enExample) | ||
| JP2010516229A5 (enExample) | ||
| JP2018108086A5 (enExample) | ||
| RU2009129403A (ru) | Антитела, нейтрализующие цитомегаловирус человека, и их применение | |
| HRP20201345T1 (hr) | Protutijela koja snažno neutraliziraju virus hepatitisa b i njihova upotreba | |
| JP2016503413A5 (enExample) | ||
| RU2014146503A (ru) | Белки, связывающие антиген - лиганд cd30 человека | |
| JP2020500538A5 (enExample) | ||
| JP2019504032A5 (enExample) | ||
| RU2588467C3 (ru) | Стабильные и растворимые антитела, ингибирующие vegf | |
| IL259940B2 (en) | Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (gipr) in combination with glp-1 agonists | |
| JP2025032102A5 (enExample) | ||
| JP2021501579A5 (enExample) | ||
| JP2015522252A5 (enExample) | ||
| JP2019533425A5 (enExample) | ||
| JP2011528901A5 (enExample) | ||
| JP2022525377A5 (enExample) | ||
| JP2022535523A5 (enExample) |